LoginSignup
PRC

PROCEPT

Stock
Stock
Ticker: PRCT
PRCT

Price

Price

CHART BY

Frequently asked questions

What is PROCEPT's market capitalization?

The market capitalization of PROCEPT is $1.99B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for PROCEPT?

PROCEPT's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.557. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for PROCEPT's stock?

Currently, 13 analysts cover PROCEPT's stock, with a consensus target price of $66.45. Analyst ratings provide insights into the stock's expected performance.

What is PROCEPT's revenue over the trailing twelve months?

Over the trailing twelve months, PROCEPT reported a revenue of $274.95M.

What is the EBITDA for PROCEPT?

PROCEPT's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$85.92M. EBITDA measures the company's overall financial performance.

What is the free cash flow of PROCEPT?

PROCEPT has a free cash flow of -$89.27M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does PROCEPT have, and what sector and industry does it belong to?

PROCEPT employs approximately 756 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.

What is the free float of PROCEPT's shares?

The free float of PROCEPT is 52.65M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$1.99B
EPS (TTM) 
-$1.557
Free Float 
52.65M
Revenue (TTM) 
$274.95M
EBITDA (TTM) 
-$85.92M
Free Cashflow (TTM) 
-$89.27M

Pricing

52W span
$35.31$103.53

Analyst Ratings

The price target is $66.45 and the stock is covered by 13 analysts.

Buy

11

Hold

2

Sell

0

Information

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

Employees
756
Industries
Medical Specialties
Sector
Health Care

Identifier

Primary Ticker
PRCT
Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin